Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi (EURONEXT: SAN and NYSE: SNY) has announced at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR?, a new half unit insulin reusable pen that can be used with Lantus? (insulin glargine), Apidra? (insulin glulisine) or Insuman? (recombinant human insulin).
Delivering from 1 to 30 units per injection, JuniorSTAR? is an easy-to-use lightweight pen with a large dose display and a single-step dial back that does not leak insulin. JuniorSTAR? has been developed and is manufactured by Sanofi's partner Haselmeier GmbH, Stuttgart, Germany.
http://www.hospitalhealthcare.com/d...itle=CE_Mark_for_JuniorSTAR®&article.id=30237
Delivering from 1 to 30 units per injection, JuniorSTAR? is an easy-to-use lightweight pen with a large dose display and a single-step dial back that does not leak insulin. JuniorSTAR? has been developed and is manufactured by Sanofi's partner Haselmeier GmbH, Stuttgart, Germany.
http://www.hospitalhealthcare.com/d...itle=CE_Mark_for_JuniorSTAR®&article.id=30237